AVRO News and Press, AVROBIO Inc. From 11/17/20

Avrobio (AVRO) announces positive data across its clinical programs in Gaucher disease type 1, Fabry disease and cystinosis. New clinical updates announced today include:AVR-RD-02 for Gaucher disease type 1: Positive early reductions in plasma lyso-Gb1 and chitotriosidase activity at three mo...

Three months post-gene therapy, first patient in Gaucher trial shows reductions in the toxic metabolite plasma lyso-Gb1 and plasma chitotriosidase as compared to baseline when the patient was on ERT Ongoing Fabry disease trials continue to demonstrate sustained durability, wit...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

AVROBIO (AVRO): Q3 GAAP EPS of -$1.01 misses by $0.19.Cash and cash equivalents of $219.5MPress Release For further details see: AVROBIO EPS misses by $0.19

Expanded ex vivo lentiviral gene therapy pipeline with program for Hunter syndrome Received orphan drug designation from the European Commission for two lead programs, AVR-RD-01 for Fabry disease and AVR-RD-02 for Gaucher disease type 1 Clinical and pipeline updates to...

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-01, the company’s investigational ge...

Event to be webcast on Tuesday, Nov. 17, 2020 at 9:00 a.m. ET AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will host a Virtual R&D Day for analyst...

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Gail M. Farfel, Ph.D., to its Board of Directors. Dr. Farfel brings more than 25 years of pharmaceutical d...

AVROBIO (AVRO) has entered into an exclusive, license agreement and collaborative research funding agreement with The University of Manchester for an investigational lentiviral gene therapy (AVR-RD-05) for mucopolysaccharidosis type II (MPS II), or Hunter syndrome.The Phase 1/2 trial for...

Investigational gene therapy licensed from The University of Manchester, UK aims to address both physical and CNS manifestations of Hunter syndrome Expands leading pipeline targeting lysosomal disorders with 5 th investigational gene therapy Program expected to ent...